Perry Wilson
Yale University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Perry Wilson as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:26 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06111768 · Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility StudyYale University · completed · Cardiorenal Syndrome · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:26 UTC. The ranking covers the 200 most relevant of 224 PubMed records, and a shared surname and initials can bring in a namesake. All 224 on PubMed
- 872 citationsRCR 16.8
- 555 citationsRCR 14.5
- 514 citationsRCR 18.4
- 486 citationsRCR 18.2
- Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study.Arch Neurol · 2006484 citationsRCR 13.1
- 309 citationsRCR 16.2
- Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial.Diabetes Care · 2009247 citationsRCR 6.4
- 244 citationsRCR 7.1
- Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans.Proc Natl Acad Sci U S A · 2014214 citationsRCR 5.6
- 205 citationsRCR 7.3